Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9435583 | 0.93 | SIGMAR1 (0.58) | SLC6A3SIGMAR1HTR1ADRD2HRH3 | |
| SCHEMBL14423336 | 0.81 | SIGMAR1 (0.55) | SIGMAR1HRH3 | |
| SCHEMBL18768681 | 0.76 | SIGMAR1 (0.53) | SLC6A3SIGMAR1 | |
| SCHEMBL8668531 | 0.75 | SLC6A3 (0.70) | SLC6A3SIGMAR1HTR1ADRD2HRH3 | |
| SCHEMBL6272610 | 0.74 | SIGMAR1 (0.52) | SLC6A3SIGMAR1HRH3 | |
| Hydrochloric Acid SCHEMBL7983455 | 0.74 | SLC6A3 (0.68) | SLC6A3SIGMAR1HTR1ADRD2HRH3 | |
| SCHEMBL41969 | 0.73 | SIGMAR1 (0.79) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL3963041 | 0.73 | SIGMAR1 (0.79) | SLC6A3SIGMAR1HTR1ADRD2ACHE | |
| SCHEMBL23010613 | 0.72 | NISCH (0.41) | SIGMAR1HRH3MAOA | |
| Hydrochloric Acid SCHEMBL16739273 | 0.72 | SIGMAR1 (0.77) | SLC6A3SIGMAR1HTR1ADRD2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379558-B1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546406-B2 | Heterocyclic compounds as metap-2 inhibitors | MERCK PATENT GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-17 | — | — | US | disclosed |
| WO-2010083870-A1 | NOVEL HETEROCYCLIC COMPOUNDS FOR USE AS METAP-2 INHIBITORS | MERCK PATENT GMBH (DE) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281859-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS METAP-2 INHIBITORS | METAP2, METAP1, XPNPEP2 | SLC6A3 2860/4885SIGMAR1 1978/4885HTR1A 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.